Gastrointestinal Events with Clopidogrel: A Nationwide Population-Based Cohort Study
- 319 Downloads
Clopidogrel prevents cardiovascular events, but has been linked with adverse gastrointestinal (GI) complications, particularly bleeding events.
We aimed to investigate the risk of adverse GI events in patients treated with clopidogrel.
A nationwide population-based cohort study based on linkage of three administrative registries in Denmark.
All individuals who redeemed at least one prescription of clopidogrel from 1996 to 2008 were included as exposed subjects (n = 77,503). For each exposed subject, three matched controls were randomly selected from the background population (n = 232,510).
Follow-up began on January 1, 1996, and was censored on December 31, 2007, or if patients emigrated or died. The study endpoint was the occurrence of any gastritis, GI ulcer or bleeding. Analyses were adjusted for comorbidity and medication.
Regardless of dose, adjusted odds ratios associating clopidogrel use with the study endpoint were statistically significant and followed a dose–response pattern. The crude absolute risk of GI events were: never users: 2.2 %; <0.1 defined daily dose (DDD) of clopidogrel per day: 7.1 %; 0.1–0.39 DDD: 6.0 %; 0.4–0.79 DDD: 5.7 %; ≥0.80 DDD: 4.4 %. Adjusted odds ratios were: <0.1 DDD: 1.34, 95 % CI: 1.26–1.42; 0.1–0.39 DDD: 1.58, 95 % CI: 1.48–1.68; 0.4–0.79 DDD: 1.91, 95 % CI: 1.77–2.06; ≥0.80 DDD: 1.77, 95 % CI: 1.66–1.89, all p-values < 0.01. Depending on the dose, numbers needed to harm ranged from 58 to 33 patients receiving 12 months of clopidogrel treatment.
The well-known cardioprotective effect of clopidogrel must be carefully weighed against an increased risk of GI events.
KEY WORDSclopidogrel coronary artery disease gastritis gastrointestinal hemorrhage stomach ulcer
Anatomical Therapeutical Chemical
Defined daily dose
International Classification of Diseases
- 1.Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909–2945.PubMedCrossRefGoogle Scholar
- 2.Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054.PubMedCrossRefGoogle Scholar
- 4.Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316(7141):1337–1343.PubMedCrossRefGoogle Scholar
- 10.Nikolsky E, Stone GW, Kirtane AJ, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;54(14):1293–1302.PubMedCrossRefGoogle Scholar
- 12.Schmidt M, Riis AH, Christiansen CF, Lash TL, Sorensen HT. Clopidogrel Use and Short-Term Mortality After Peptic Ulcer Bleeding: A Population-Based Cohort Study. Am J Ther 2011 Feb 15. doi: 10.1097/MJT.0b013e3181ff7ad1.
- 18.Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010;56(24):2051–2066.PubMedCrossRefGoogle Scholar
- 20.Wurtz M, Grove EL. Combining aspirin and proton pump inhibitors: For whom the warning bell tolls? Expert Opin Drug Metab Toxicol. 2012. doi:10.1517/17425255.2012.711318
- 22.IMS. Global Prescription Sales Information. Top 20 Global Products, 2010. (http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-line%20Market%20Data/2010%20Top-line%20Market%20Data/Top_20_Global_Products.pdf). Accessed 22 July, 2012.
- 27.WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2010. Oslo. 2011.Google Scholar
- 34.Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967–1974.PubMedCrossRefGoogle Scholar